Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

Human Papillomavirus Genotype Distribution Among 18,815 Women in 13 Korean Cities and Relationship With Cervical Cytology Findings

  • Nah, Eun-Hee (Department of Laboratory Medicine and Health Promotion Research Institute, Korea Association of Health Promotion) ;
  • Cho, Seon (Department of Laboratory Medicine and Health Promotion Research Institute, Korea Association of Health Promotion) ;
  • Kim, Suyoung (Department of Laboratory Medicine and Health Promotion Research Institute, Korea Association of Health Promotion) ;
  • Cho, Han-Ik (MEDIcheck LAB, Korea Association of Health Promotion)
  • Received : 2016.11.08
  • Accepted : 2017.05.26
  • Published : 2017.09.01
⟨ Previous Next ⟩

Abstract

Background: The prevalence and genotype distribution of Human papillomavirus (HPV) infection vary depending on geographical region and the immunity provided by vaccines. This study aimed to clarify the recent prevalence and genotype distribution of HPV according to age and cervical cytology findings in Korea. Methods: This study included 18,815 health examinees that underwent cervical cytology and HPV genotyping tests at 16 centers of Korean Association of Health Promotion in 13 cities in Korea, between January 2014 and October 2015. HPV was genotyped by using multiplex PCR (Anyplex II HPV 28, Seegene, Korea), which detects 19 high-risk HPVs (HR-HPV) and nine low-risk HPVs (LR-HPV). Results: Overall HPV prevalence was 27.8%, with 22.2% HR-HPV and 11.4% LR-HPV. The five most common carcinogens were HPV 52 (3.2%), 58 (2.7%), 16 (2.0%), 56 (1.9%), and 51 (1.8%). The five most common HR-HPVs in normal cytology samples were HPV 53, 68, 70, 52, and 58, while HPV 16, 52, 58, 33, and 31 were prevalent in high grade squamous intraepithelial lesions (HSIL). In atypical squamous cells of undetermined significance (ASCUS), the prevalence of HR-HPV varied with age; it was highest in those aged <30 yr, declining to a minimum at age 50-59 yr, and then increasing in older women (P <0.05). Conclusions: The prevalence and distribution of HR-HPV varied with age and cervical cytology findings. This information would be helpful in the development of cervical cancer prevention policies.

Keywords

Acknowledgement

Supported by : Korean Association of Health Promotion

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108. https://doi.org/10.3322/caac.21262
  2. National Cancer Center. Annual report of cancer statistics in Korea in 2014. Goyang, Korea: National Cancer Center, 2014:20-2.
  3. Meijer CJ, Snijders PJ, Castle PE. Clinical utility of HPV genotyping. Gynecol Oncol 2006;103:12-7. https://doi.org/10.1016/j.ygyno.2006.07.031
  4. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012;137:516-42. https://doi.org/10.1309/AJCPTGD94EVRSJCG
  5. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010;401:70-9. https://doi.org/10.1016/j.virol.2010.02.002
  6. de Sanjosc S, Diaz M, Castellsaguc X, Clifford G, Bruni L, Munoz N, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007;7:453-9. https://doi.org/10.1016/S1473-3099(07)70158-5
  7. Bae JH, Lee SJ, Kim CJ, Hur SY, Park YG, Lee WC, et al. Human papillomavirus (HPV) type distribution in Korean women: a meta-analysis. J Microbiol Biotechnol 2008;18:788-94.
  8. Kim MJ, Kim JJ, Kim S. Type-specific prevalence of high-risk human papillomavirus by cervical cytology and age: Data from the health check-ups of 7,014 Korean women. Obstet Gynecol Sci 2013;56:110-20. https://doi.org/10.5468/OGS.2013.56.2.110
  9. Shin HR, Lee DH, Herrero R, Smith JS, Vaccarella S, Hong SH, et al. Prevalence of human papillomavirus infection in women in Busan, South Korea. Int J Cancer 2003;103:413-21. https://doi.org/10.1002/ijc.10825
  10. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9. https://doi.org/10.1001/jama.287.16.2114
  11. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009;4:8. https://doi.org/10.1186/1750-9378-4-8
  12. IARC. Agents classified by the IARC monographs, vol. 1-118. http://monographs.iarc.fr/ENG/Classification/index.php (Updated on May 2017).
  13. Kim JK, Jeon JS, Lee CH, Kim JW. Prevalence and genotype distribution of human papillomavirus in Cheonan, Korea. J Microbiol Biotechnol 2014;24:1143-7. https://doi.org/10.4014/jmb.1405.05020
  14. Lee EH, Um TH, Chi HS, Hong YJ, Cha YJ. Prevalence and distribution of human papillomavirus infection in Korean women as determined by restriction fragment mass polymorphism assay. J Korean Med Sci 2012; 27:1091-7. https://doi.org/10.3346/jkms.2012.27.9.1091
  15. Rhee JE, Shin MY, Kim CM, Kee HY, Chung JK, Min SK, et al. Prevalence of human papillomavirus infection and genotype distribution among high-risk Korean women for prospecting the strategy of vaccine development. Virol J 2010;7:201. https://doi.org/10.1186/1743-422X-7-201
  16. Mesher D, Panwar K, Thomas SL, Beddows S, Soldan K. Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study. BMJ Open 2016;6:e009915. https://doi.org/10.1136/bmjopen-2015-009915
  17. Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013;208:385-93. https://doi.org/10.1093/infdis/jit192
  18. Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012;206:1645-51. https://doi.org/10.1093/infdis/jis590
  19. Heard I, Tondeur L, Arowas L, Falguieres M, Demazoin MC, Favre M. Human papillomavirus types distribution in organised cervical cancer screening in France. PLoS One 2013;8:e79372. https://doi.org/10.1371/journal.pone.0079372
  20. Howell-Jones R, Bailey A, Beddows S, Sargent A, de Silva N, Wilson G, et al. Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England. Br J Cancer 2010;103:209-16. https://doi.org/10.1038/sj.bjc.6605747
  21. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008;26(S10):K1-16. https://doi.org/10.1016/j.vaccine.2008.05.064
  22. Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012;12:781-9. https://doi.org/10.1016/S1473-3099(12)70187-1
  23. Wheeler CM, Castellsaguc X, Garland SM, Szarewski A, Paavonen J, Naud P, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:100-10. https://doi.org/10.1016/S1470-2045(11)70287-X
  24. Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006;119:2677-84. https://doi.org/10.1002/ijc.22241
  25. Gravitt PE, Rositch AF, Silver MI, Marks MA, Chang K, Burke AE, et al. A cohort effect of the sexual revolution may be masking an increase in human papillomavirus detection at menopause in the United States. J Infect Dis 2013;207:272-80. https://doi.org/10.1093/infdis/jis660
  26. Althoff KN, Paul P, Burke AE, Viscidi R, Sangaramoorthy M, Gravitt PE. Correlates of cervicovaginal human papillomavirus detection in perimenopausal women. J Womens Health (Larchmt) 2009;18:1341-6. https://doi.org/10.1089/jwh.2008.1223
  27. Munoz N, Mcndez F, Posso H, Molano M, van den Brule AJ, Ronderos M, et al; Instituto Nacional de Cancerologia HPV Study Group. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004;190:2077-87. https://doi.org/10.1086/425907

Cited by

  1. Human Papilloma Viruses and Their Genotype Distribution in Women with High Socioeconomic Status in Central Anatolia, Turkey: A Pilot Study vol.24, pp.None, 2017, https://doi.org/10.12659/msm.906652
  2. Updates on Cancer Epidemiology in Korea, 2018 vol.54, pp.2, 2017, https://doi.org/10.4068/cmj.2018.54.2.90
  3. Burden of Human papillomavirus (HPV)-related disease and potential impact of HPV vaccines in the Republic of Korea vol.7, pp.None, 2017, https://doi.org/10.1016/j.pvr.2018.12.002
  4. HPV-16, HPV-58, and HPV-33 are the most carcinogenic HPV genotypes in Southwestern China and their viral loads are associated with severity of premalignant lesions in the cervix vol.15, pp.1, 2017, https://doi.org/10.1186/s12985-018-1003-x
  5. Cervical human papillomavirus among 19 753 women attending gynecological department of a major comprehensive hospital in north Anhui China 2013‐2016: Implication for cervical cancer screening an vol.91, pp.4, 2017, https://doi.org/10.1002/jmv.25365
  6. 부산지역 여성의 고위험군 인유두종 바이러스 유병률과 유전자형 분석 vol.29, pp.11, 2019, https://doi.org/10.5352/jls.2019.29.11.1267
  7. Correlation of Swede score colposcopy scoring system and histopathological results in patients with high-risk HPV infection other than HPV16 and 18 vol.30, pp.1, 2017, https://doi.org/10.1136/ijgc-2019-000932
  8. Fifteen new nucleotide substitutions in variants of human papillomavirus 18 in Korea : Korean HPV18 variants and clinical manifestation vol.17, pp.1, 2017, https://doi.org/10.1186/s12985-020-01337-7
  9. A New Strategy for Elimination of Human Paplloma Virus-related Disease after Human Papillomavirus Vaccines Introduction vol.15, pp.3, 2020, https://doi.org/10.14777/uti.2020.15.3.63
  10. Current Updates on Cancer-Causing Types of Human Papillomaviruses (HPVs) in East, Southeast, and South Asia vol.13, pp.11, 2021, https://doi.org/10.3390/cancers13112691
  11. Enhanced disease progression due to persistent HPV-16/58 infections in Korean women: a systematic review and the Korea HPV cohort study vol.18, pp.1, 2017, https://doi.org/10.1186/s12985-021-01657-2